Lantern Pharma Inc (LTRN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.60 (-6.43%), Market cap $0.04B, 52-week low–high $1.12 ~ $5.32.
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develop
Financial statements, price targets, institutional (13F) holdings and related news for Lantern Pharma Inc are updated in real time on BlackAll Trade.
Lantern Pharma Inc trades at $1.60 (-6.43%). Real-time quotes and charts are available on BlackAll Trade.
Lantern Pharma Inc has a market cap of about $0.04B.
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smoke